Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MXCT vs TMCI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TMCI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–3 Matrix Metrics)
TMCI Overall Winner
6-Pillar Tally: MXCT 0 – 5 TMCI (1 Tie)
Matrix Metrics: MXCT 3 – 5 TMCI
As of Nov 20, 2026, Treace Medical Concepts, Inc. (TMCI) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TMCI carries 42.7/100 (HOLD) at $4.31 (N/M Forward P/E, -24.4% operating margin).
- Growth vs. Quality Trade-Off: TMCI earns the overall head-to-head edge with a stronger Unified Composite Score (42.7/100 HOLD vs. MXCT 41.7/100 SELL) and 2.03β · 110% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile TMCI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About MXCT vs TMCI
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
TMCI
Head-to-Head Winner
Treace Medical Concepts, Inc. Common Stock
$4.31
-0.92% 1D
Market Cap
$285.2M
TTM Revenue
$203M
Forward P/E
N/M
Beta / 30D Vol
2.03β · 110% Vol
Unified Composite Score
42.7
HOLD
Tech 25.0
Fund 45.0
Flow 67.0
Mom 50.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (MXCT 0 – 5 TMCI)
1. Valuation Multiples
TMCI
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.9x
1.7x
2. Growth & Scale
TMCI
Revenue Growth (YoY)
+48.7%
-3.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$34M
$203M
Market Cap
$132.2M
$285.2M
3. Profitability & Quality
TMCI
Gross Margin
81.0%
79.6%
Operating Margin
-85.5%
-24.4%
Net Profit Margin
-81.4%
-27.4%
Return on Equity (ROE)
-16.9%
-74.0%
4. Balance Sheet & Cash Flow
TMCI
Cash Generation (TTM)
-$24M
-$19M
Cash Flow Margin
-69.2%
-9.1%
Net Cash / Leverage
$2.2M Net Debt (0.11x D/E)
$67M Net Debt (1.21x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
TMCI
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
547.9% (100th %ile)
Put/Call OI Skew
N/A
0.34x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: MXCT (3) vs TMCI (5)| Institutional Metric | MXCT | TMCI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $132.2M | $285.2M | TMCI | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +48.7% | -3.9% | MXCT | |
| Operating Margin (TTM) | -85.5% | -24.4% | TMCI | |
| Net Profit Margin | -81.4% | -27.4% | TMCI | |
| Return on Equity (ROE) | -16.9% | -74.0% | MXCT | |
| 52-Week Range Position | 63% ($1–$2) | 74% ($1–$5) | TMCI | |
| Beta / 30D Volatility | 1.19β · 96% Vol | 2.03β · 110% Vol | MXCT | |
| Unified Institutional Score | 41.7 / 100 (SELL) | 42.7 / 100 (HOLD) | TMCI | |
| Trailing 12M Revenue (USD) | $34M | $203M | Scale | |
| Gross Profit Margin (TTM) | 81.0% | 79.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.9x EV/Rev | N/M PEG · 1.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$24M ($2.2M Net Debt (0.11x D/E)) | -$19M ($67M Net Debt (1.21x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
TMCI +4.9 pp
3M Horizon
TMCI +0.07 pp
6M Horizon
TMCI +23.31 pp
1Y Horizon
TMCI +77.87 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MXCT Revenue | TMCI Revenue | MXCT Op. Margin | TMCI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $40M | -93.7% | -9.0% | TMCI |
| FY2020 | $20M | $60M | -71.6% | 1.5% | TMCI |
| FY2021 | $20M | $90M | -84.3% | -17.5% | TMCI |
| FY2022 | $30M | $140M | -95.2% | -24.6% | TMCI |
| FY2023 | $20M | $190M | -247.7% | -27.5% | TMCI |
| FY2024 | $20M | $210M | -230.5% | -26.6% | TMCI |
| FY2025 | $20M | $210M | -247.6% | -25.5% | TMCI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
TMCI
CONSOLIDATION
Current IV
547.9%
IV Percentile
100th %ile
Put/Call OI Skew
0.34x (Call-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact TMCI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
TMCI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ MXCT vs TMCI Key Questions & Quantitative Answers
As of Nov 20, 2026, Treace Medical Concepts, Inc. (TMCI) is the stronger overall head-to-head candidate over MaxCyte, Inc. (MXCT) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MXCT carries a Unified Composite Score of 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin), whereas TMCI carries 42.7/100 (HOLD) at $4.31 (N/M Forward P/E, -24.4% operating margin). Growth vs. Quality Trade-Off: TMCI earns the overall head-to-head edge with a stronger Unified Composite Score (42.7/100 HOLD vs. MXCT 41.7/100 SELL) and 2.03β · 110% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3); meanwhile TMCI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TMCI leads the Growth & Scale pillar: MXCT posts +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin), compared with TMCI at -3.9% YoY revenue growth and +0.0% YoY earnings growth on $203M TTM revenue (79.6% gross margin, -24.4% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), MXCT cumulative revenue shifted +100.0% while TMCI shifted +425.0%. In operating R&D and SG&A reinvestment, MXCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TMCI.
TMCI screens cheaper on headline valuation multiples. MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin), whereas TMCI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.7x EV/Revenue (-9.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MXCT (-16.9% ROE) versus TMCI (-74.0% ROE) capital efficiency.
In options market volatility and institutional positioning, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk). By comparison, TMCI carries 547.9% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.34x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.03β · 110% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
TMCI vs MXCT · Reverse Pair
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
MXCT vs RLYB
· Sector Peer
TMCI vs SGHT
· Sector Peer
TMCI vs CTKB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem